Trial Profile
Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Metablok-Arch Biopartners (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Acronyms CS-AKI
- Sponsors Arch Biopartners
- 16 Apr 2024 According to an Arch Biopartners media release, St. Michaels Hospital clinical team is awaiting ethics approval prior to beginning enrolment in the trial, The addition of St. Michaels as the third Canadian clinical site increases the number of trial sites to nine, with six hospitals in Turkey currently recruiting patients.
- 16 Apr 2024 According to an Arch Biopartners media release, the company announced that a research team from St. Michaels Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI)
- 03 Apr 2024 According to an Arch Biopartners media release, Anesthesia Clinical Trials Unit (ACTU), an academic research organization in the Department of Anesthesia and Pain Management at the University Health Network (UHN), has joined this Phase II trial